Company Analysis

BioLineRx Ltd. (BLRX)

Nasdaq: BLRX · Pharmaceutical Preparations · filing with the SEC since 2010
Grade4.2
◀ Past 4.2● Present 4.3▶ Future 4.1
2 est.

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

19 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to BioLineRx Ltd.’s names, not what it holds today.

Patents granted
19
19 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against 1 in 2024 and 10 in 2023
Applications published
53
5 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'09'10'12'13'16'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals14
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
BioLineRx Ltd. its own name
IL, as the owner printed on each patent
19 granted
46 published
BioLineRx Ltd. its own name
named as the applicant on its applications, in IL. 1 more under the same name are not counted (printed in US)
0 granted
7 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
May 6, 202512,291,570Treatment of metastatic pancreatic adenocarcinomaPharmaceuticalsBioLineRx Ltd.
Apr 8, 202512,268,725Composition of BL-8040PharmaceuticalsBioLineRx Ltd.
Mar 25, 202512,257,285Composition of BL-8040PharmaceuticalsBioLineRx Ltd.
May 28, 202411,993,631Process for manufacturing peptideBiotechnologyBioLineRx Ltd.
May 16, 202311,648,293Compositions and methods for treating cancerPharmaceuticalsBioLineRx Ltd.
May 9, 202311,642,393Compositions and methods for treating cancerPharmaceuticalsBioLineRx Ltd.
May 2, 202311,638,743Compositions and methods for treating cancerPharmaceuticalsBioLineRx Ltd.
May 2, 202311,638,742Compositions and methods for treating cancerPharmaceuticalsBioLineRx Ltd.
Mar 28, 202311,612,638Compositions and methods for treating cancerPharmaceuticalsBioLineRx Ltd.
Mar 21, 202311,607,444Compositions and methods for treating cancerPharmaceuticalsBioLineRx Ltd.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jun 19, 20252025/0195607COMPOSITION OF BL-8040PharmaceuticalsBioLineRx Ltd.
May 29, 20252025/0170208COMPOSITION OF BL-8040PharmaceuticalsBioLineRx Ltd.
May 29, 20252025/0170207COMPOSITION OF BL-8040PharmaceuticalsBioLineRx Ltd.
May 29, 20252025/0170206COMPOSITION OF BL-8040PharmaceuticalsBioLineRx Ltd.
May 29, 20252025/0170205COMPOSITION OF BL-8040PharmaceuticalsBioLineRx Ltd.
Apr 25, 20242024/0131111COMPOSITION OF BL-8040PharmaceuticalsBioLineRx Ltd. · patent 12,257,285 granted from it
Mar 21, 20242024/0092827PROCESS FOR MANUFACTURING PEPTIDEBiotechnologyBioLineRx Ltd. · patent 11,993,631 granted from it
Mar 14, 20242024/0082348COMPOSITION OF BL-8040PharmaceuticalsBioLineRx Ltd. · patent 12,268,725 granted from it
Aug 3, 20232023/0242644TREATMENT OF METASTATIC PANCREATIC ADENOCARCINOMAPharmaceuticalsBioLineRx Ltd.
Apr 6, 20232023/0104343CXCR4 INHIBITOR FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND VIRAL INFECTIONSPharmaceuticalsBioLineRx Ltd.
What it applied for, 2024 to 2025: Pharmaceuticals 7 · Biotechnology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton BLRX · research, not advice